Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
作者： Christopher M. Overall , Oded Kleifeld
DOI: 10.1038/NRC1821
关键词:
摘要: The matrix metalloproteinases (MMPs) mediate homeostasis of the extracellular environment. They have multiple signalling activities that are commonly altered during tumorigenesis and might serve as intervention points for anticancer drugs. However, there many criteria to consider in validating MMPs drug targets development MMP inhibitors. inhibition some could pro-tumorigenic effects (making them anti-targets), counterbalancing benefits target inhibition. These partially account failure inhibitors clinical trials. What major challenges validation MMP-inhibitor-drug development?
nature.com
sci-hub.se 参考文章(106)
Neal M Davies, Fakhreddin Jamali, COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences. ,vol. 7, pp. 332- 336 ,(2004)
C M Overall, J Sodek, Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. Journal of Biological Chemistry. ,vol. 265, pp. 21141- 21151 ,(1990) , 10.1016/S0021-9258(17)45338-5
Isaiah J. Fidler, The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited Nature Reviews Cancer. ,vol. 3, pp. 453- 458 ,(2003) , 10.1038/NRC1098
A Ben-Baruch, Host microenvironment in breast cancer development: Inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor–microenvironment interactions Breast Cancer Research. ,vol. 5, pp. 31- 36 ,(2002) , 10.1186/BCR554
Shigeyoshi Itohara, Masatoshi Tanioka, Hiroshi Yoshida, Hirofumi Nishimoto, Takeshi Itoh, Takayuki Yoshioka, Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Research. ,vol. 58, pp. 1048- 1051 ,(1998)
Gabriele Bergers, Rolf Brekken, Gerald McMahon, Thiennu H. Vu, Takeshi Itoh, Kazuhiko Tamaki, Kazuhiko Tanzawa, Philip Thorpe, Shigeyoshi Itohara, Zena Werb, Douglas Hanahan, Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis Nature Cell Biology. ,vol. 2, pp. 737- 744 ,(2000) , 10.1038/35036374
Thomas Boehm, Judah Folkman, Timothy Browder, Michael S. O'Reilly, Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance Nature. ,vol. 390, pp. 404- 407 ,(1997) , 10.1038/37126
Hideaki Nagase, Takashi Shinya, Isao Ohno, Ko Suzuki, Katsunori Kumagai, Kunio Shirato, Kazushi Iwata, Shinji Okada, Yuichi Ohkawara, Inhibition of Matrix Metalloproteinases Prevents Allergen-Induced Airway Inflammation in a Murine Model of Asthma Journal of Immunology. ,vol. 162, pp. 4212- 4219 ,(1999)
J M Arbeit, K Münger, P M Howley, D Hanahan, Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. Journal of Virology. ,vol. 68, pp. 4358- 4368 ,(1994) , 10.1128/JVI.68.7.4358-4368.1994
David T. Puerta, Seth M. Cohen, Examination of novel zinc-binding groups for use in matrix metalloproteinase inhibitors. Inorganic Chemistry. ,vol. 42, pp. 3423- 3430 ,(2003) , 10.1021/IC026029G